Drug Fix: US FDA’s Prasad Leaves, Harry Potter, And Is CNPV Effective Because Of RTOR?

What It Covers

Vinay Prasad's departure from CBER leadership creates a second senior FDA vacancy in under a year, while analysis of the Commissioner's National Priority Review Voucher program reveals its fastest approvals rely heavily on the pre-existing Real-Time Oncology Review framework rather than the CNPV mechanism itself.

Key Questions Answered

• •CBER Leadership Succession: With Prasad departing in late April 2026, McCary has roughly six weeks to name a replacement — too short for traditional federal hiring. Internal candidates are most likely, including CBER deputy director Catherine Zarema or CDER director Tracy Beth Hogue, who has publicly engaged with vaccine policy despite it falling outside CDER's jurisdiction.
• •Vaccine Policy Continuity Risk: Sponsors expecting Prasad's departure to reset vaccine approval standards should temper expectations. RFK Jr.'s influence over vaccine policy remains intact regardless of who leads CBER, meaning the administration's anti-vaccine posture will likely persist through the upcoming Moderna mRNA flu vaccine decision, which carries a mandatory user fee deadline.
• •CNPV Speed Is Borrowed, Not New: The two fastest CNPV approvals — J&J's Tecvayli/Darzalex Faspro combo at 86 days and Hernexios at 104 days — rank only 13th and 18th on the all-time RTOR speed chart. Both were already in the RTOR pipeline before receiving CNPV designation, meaning the voucher program is accelerating reviews already primed by an older, established mechanism.
• •FDA Review Speed Has Declined Since 2021: Between 2015 and 2021, 14% of all novel FDA approvals had review times of six months or less. Since 2021, no novel agent has been approved in under six months. The CNPV program's speed rhetoric contrasts with this documented slowdown, and industry's actual preference has shifted toward predictability over raw speed.
• •RTOR Scalability Limits Apply to CNPV: RTOR succeeded in oncology because binary life-or-death endpoints made trade-off assessments straightforward and the oncology office operated with relative autonomy. Attempts to replicate this model broadly — including the STAR program, which was dropped in PDUFA negotiations after zero uptake — show that universal fast-track frameworks generate bureaucratic overhead that erodes the speed advantage they promise.